ATS: CT Screening Finds High Lung Cancer Rate at Veterans Affairs Center

This article originally appeared here.
Share this content:
ATS: Lung Cancer Diagnosis 7 Percent With Low-Dose CT
ATS: Lung Cancer Diagnosis 7 Percent With Low-Dose CT

(HealthDay News) -- The preliminary rate of lung cancer diagnosis using low-dose computed tomography (CT) screening is 7% at a Veterans Affairs Medical Center, according to a study presented at the annual meeting of the American Thoracic Society, held from May 17 to 22 in Philadelphia.

Sue H. Yoon, N.P., from VA Boston HealthCare, and colleagues enrolled 56 patients with either a history of more than 30 pack-years or 20 pack-years with one additional risk factor (median age, 61 to 65 years) to describe the screening experience at a Veterans Affairs Medical Center.

The researchers found that more than 80% of participants had more than a 30 pack-year history, half of whom were current smokers. Only three patients had no nodules, while 60% had more than one nodule and 55% (31 patients) had a nodule of 4 mm or larger or other abnormal opacity. For six of these 31 patients, the nodule was deemed suspicious for malignancy based on size and morphological characteristics. Biopsy-proven lung cancer was diagnosed in four patients (7%) and included one case each of stage 1A adenocarcinoma, stage 1B adenocarcinoma, stage 3A adenocarcinoma, and stage 3B squamous cell carcinoma.

"Our preliminary rate of lung cancer diagnosis after the first round of screening was 7%, which was significantly higher than the National Lung Cancer Screening Trial group, which had a preliminary rate of 3.8% at its first round," Yoon said in a statement.

More Information

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs